Emfogen M XR 25 mg+1000 mg (Tablet (Extended Release))

Unit Price: ৳ 45.00 (2 x 6: ৳ 540.00)
Strip Price: ৳ 270.00

Medicine Details

Category Details
Generic Empagliflozin metformin hydrochloride
Company General pharmaceuticals ltd
Also available as
Emfogen m 5 mg tablet Emfogen m xr 5 mg tablet Emfogen m xr 10 mg tablet Emfogen m 5 mg tablet Emfogen m 125 mg tablet Emfogen m 125 mg tablet

Indications

  • Treatment of adults with type 2 diabetes mellitus as an adjunct to diet and exercise
  • Insufficiently controlled on maximally tolerated dose of Metformin alone
  • In combination with other medicinal products for diabetes treatment
  • Already being treated with the combination of Empagliflozin and Metformin as separate tablets

Pharmacology

  • Empagliflozin is an inhibitor of Sodium-Glucose Co-Transporter 2 (SGLT2)
  • Reduces renal reabsorption of filtered glucose and lowers the renal threshold for glucose
  • Metformin Hydrochloride is a biguanide type oral antihyperglycemic drug
  • Lowers basal and postprandial plasma glucose without producing hypoglycemia

Dosage & Administration

  • Should be individualized based on effectiveness and tolerability
  • Take this combination twice daily with meals
  • Gradual dose escalation to reduce gastrointestinal side effects
  • Extended-release formulations available
  • Adjust dosing based on effectiveness and tolerability
  • Assess renal function before initiating this combination

Interaction

  • Co-administration of Empagliflozin with diuretics increases urine volume and frequency of voids
  • Risk for hypoglycemia with insulin or insulin secretagogues
  • Monitoring glycemic control with urine glucose tests is not recommended
  • Drugs that reduce Metformin clearance may increase the accumulation of Metformin
  • Carbonic Anhydrase Inhibitors may increase risk of lactic acidosis
  • Alcohol can potentiate the effect of Metformin on lactate metabolism

Contraindications

  • Hypersensitivity to Empagliflozin and Metformin
  • Acute metabolic acidosis (e.g., lactic acidosis, diabetic ketoacidosis)
  • Severe renal failure (GFR <30 ml/min)
  • Conditions such as dehydration, severe infection, shock
  • Diseases causing tissue hypoxia (e.g., decompensated heart failure, respiratory failure)

Side Effects

  • Most common adverse reactions associated with Empagliflozin and Metformin
  • Common adverse reactions with Metformin: diarrhea, nausea/vomiting, flatulence, abdominal discomfort
  • Important adverse reactions: hypoglycemia, genital infections, urinary tract infection, thirst, taste disturbance
  • Rare adverse reaction: diabetic ketoacidosis

Pregnancy & Lactation

  • Potential risk to fetus, especially during second and third trimesters
  • Not recommended during breastfeeding

Precautions & Warnings

  • Lactic Acidosis is a potential risk
  • Assess and correct volume status before initiating therapy
  • Assess patients with signs and symptoms of metabolic acidosis for ketoacidosis
  • Consider temporarily discontinuing in settings of reduced oral intake or fluid losses
  • Increased risk for urinary tract infections and genital mycotic infections
  • Consider lowering the dose of insulin secretagogue or insulin to reduce the risk of hypoglycemia

Overdose Effects

  • Single doses of up to 800 mg Empagliflozin in healthy volunteers did not show toxicity
  • Hypoglycemia not seen with Metformin doses of up to 85 g, although lactic acidosis has occurred in such circumstances
  • Lactic acidosis is a medical emergency and must be treated in hospital
  • Haemodialysis is the most effective method to remove lactate and Metformin

Therapeutic Class

  • Combination Oral hypoglycemic preparations

Storage Conditions

  • Keep below 30°C temperature
  • Protected from light & moisture
  • Keep out of the reach of children

Related Brands